A case of severe idiopathic pulmonary fibrosis effectively treated with pirfenidone

Japanese Journal of Chest Diseases

Volumn 71, Issue 11, 2012, Pages 1144-1150

  Okuda, Ryo ^a   Hagiwara, Eri ^a   Endo, Takahiro ^a   Takemura, Tamiko ^b   Ogura, Takashi ^a  

^a Kanagawa Prefectural Cardiovascular and Respiratory Diseases Center Hospital   (Japan)

^b Nippon Red Cross Hospital Center   (Japan)

Author keywords

Idiopathic pulmonary fibrosis; Pirfenidone; Respiratory function test; Usual interstitial pneumonia; Vital capacity

Indexed keywords

EID: 84870161807     PISSN: 03853667     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (8)

1. Taniguchi H, Ebina M, Kondoh Y, et al. Prifen-idone in idiopathic pulmonary fibrosis. Eur Respir J 2010; 35: 821-9.
2. Katzenstein AL, Myers JL. Idiopathic pulmonary fibrosis : clinical relevance of pathologic classification. Am J Respir Crit Care Med 1998; 157 : 1301-15.
3. American Thoracic Society/European Respiratory Society. ATS statement. Idiopathic pulmonary fibrosis : diagnosis and treatment. International consensus statement. Am J Respir Crit Care Med 2000; 161 : 646-64.
4. Bjoraker JA, Ryu JH, Edwin MK, et al. Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1998 ; 157 : 199-203.
5. Schwartz DA, Helmers RA, Galvin JR, et al. Determinants of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1994 ; 149 : 450-4.
6. Lyer SN, Wild JS, Schiedt MJ, et al. Dietary intake of pirfenidone ameliorates bleomycin-induced lung fibrosis in hamsters. J Lab Clin Med 1995 ; 125 : 779-85.
7. Oku H, Nakazato H, Horikawa T, et al. Pirfenidone suppresses tumor necrosis factor-alpha, enhances interleukin-10 and protects mice from endotoxic shock. Eur J Pahrmacol 2002 ; 446 : 167-76.
8. Zappala CJ, Latsi PI, Nicholson AG, et al. Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosis. Eur Respir J 2010 ; 35 : 830-6.